Swiss National Bank’s MoonLake Immunotherapeutics MLTX Stock Holding History

Swiss National Bank’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.15M	Hold	61,500	–	–	﹤0.01%	2104
2025 Q4	$811K	Buy	61,500 +18,500	+43%	+$218K	﹤0.01%	2233
2025 Q3	$308K	Buy	43,000 +700	+2%	+$36.5K	﹤0.01%	2313
2025 Q2	$2M	Sell	42,300 -700	-2%	-$28.5K	﹤0.01%	1813
2025 Q1	$1.68M	Hold	43,000	–	–	﹤0.01%	1871
2024 Q4	$2.33M	Hold	43,000	–	–	﹤0.01%	1762
2024 Q3	$2.17M	Buy	43,000 +12,100	+39%	+$567K	﹤0.01%	1816
2024 Q2	$1.36M	Sell	30,900 -4,400	-12%	-$186K	﹤0.01%	2011
2024 Q1	$1.77M	Hold	35,300	–	–	﹤0.01%	1907
2023 Q4	$2.13M	Sell	35,300 -4,500	-11%	-$232K	﹤0.01%	1789
2023 Q3	$2.27M	Buy	+39,800	New	+$2.2M	﹤0.01%	1752

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Swiss National Bank's MLTX Position: Q1 2026 in Review

Swiss National Bank held its MoonLake Immunotherapeutics (MLTX) position steady in Q1 2026 at 61,500 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2104.

Swiss National Bank first reported a position in MLTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $2.33M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Swiss National Bank held 61,500 shares of MoonLake Immunotherapeutics worth $1.15M as of Q1 2026.
Swiss National Bank left its MoonLake Immunotherapeutics share count unchanged in Q1 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #2104 holding.
Swiss National Bank first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 11 quarters since.
Swiss National Bank's MoonLake Immunotherapeutics position peaked at $2.33M in Q4 2024.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.